search
Back to results

The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
GIP Bolus
GIP Clamp
Oral glucose tolerance test (OGTT)
hyperglycemic clamp
Sponsored by
Diabeteszentrum Bad Lauterberg im Harz
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon-Like Peptide 1 (GLP-1), Incretin, Insulin secretion, Tachyphylaxis

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Exclusion of pregnancy
  • Exclusion of impaired glucose tolerance or type 2 diabetes in metabolical healthy subjects
  • current diagnosis of type 2 diabetes according to the guidelines of the German Diabetes Association (DDG) ( Kerner et al . 2001) in subjects of diabetes group
  • fasting glucose ≤ 150 mg/dl
  • Body-mass-index ≥ 20 kg/m²
  • Written consent

Exclusion Criteria:

  • Type 1 diabetes
  • Impaired glucose tolerance or Type 2 diabetes in metabolical healthy subjects
  • Ketone bodies urine diagnostics at least ++
  • Acidosis
  • Fasting blood glucose > 150 mg/dl
  • Body-mass-index < 20 kg/m²
  • No written consent
  • Pregnancy or unsafe contraception in women before menopause
  • Active malignancy
  • Angina as current, unsolved clinical problem
  • Inadequately treated or untreated arterial hypertension ( > 160 mmHg systolic and / or > 95 mmHg diastolic )
  • Infection / fever > 37.5 ° C
  • Treatment with glucocorticoids
  • Insulin therapy within the last three months
  • Anemia with a hemoglobin level < 12 g/dl
  • Liver function limitations
  • Renal impairment ( serum creatinine > 1.5 mg/dl )
  • Alcohol or drug abuse
  • Participation in clinical trials in the last 3 months
  • Inability or unwillingness to comply with the requirements of the Protocol
  • Known hypersensitivity to GIP

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Active Comparator

    Active Comparator

    Arm Label

    Oral glucose tolerance test

    GIP Bolus

    GIP Infusion

    Arm Description

    An oral glucose challenge (75 g)

    Hyperglycemic clamp (capillary venous glucose concentration ~ 8.5 mmol/l) with two repeated intravenous bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp

    Hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min

    Outcomes

    Primary Outcome Measures

    Insulin secretory response after GIP bolus or infusion.

    Secondary Outcome Measures

    Full Information

    First Posted
    January 28, 2016
    Last Updated
    February 1, 2016
    Sponsor
    Diabeteszentrum Bad Lauterberg im Harz
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02673554
    Brief Title
    The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP
    Official Title
    The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of Glucose-dependent Insulinotropic Polypeptide (GIP) in Patients With Type 2 Diabetes is Not Caused by Rapid Tachyphylaxis
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    May 2004 (undefined)
    Primary Completion Date
    December 2008 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Diabeteszentrum Bad Lauterberg im Harz

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    In patients with type 2 diabetes, the incretin hormone glucose-dependent insulinotropic polypeptide (GIP) has lost its insulinotropic activity, but more so after continuous versus bolus administration. The design was a two-way crossover design comparing repeated bolus injection and continuous infusion of GIP under hyperglycaemic clamp conditions. Patients were age- gender- and weight-matched with type 2 diabetes, first degree relatives of such patients, and healthy subjects. Investigators performed a: Oral glucose challenge; hyperglycemic clamp (8.5 mmol/l) with two repeated GIP bolus administrations (50 pmol/kg body weight at 30 and 120 min); and hyperglycemic clamp with continuous administration of GIP (2 pmol.kg-1.min-1 from 30-180 min). To answer the question, whether rapid tachyphylaxis occurs with regard to the insulinotropic action of GIP, investigators studied type 2-diabetic patients, their first-degree relatives, and healthy controls under hyperglycaemic clamp conditions with two GIP bolus injections 90 min apart, and compared this to a continued intravenous infusion of GIP.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes
    Keywords
    Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon-Like Peptide 1 (GLP-1), Incretin, Insulin secretion, Tachyphylaxis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Crossover Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    30 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Oral glucose tolerance test
    Arm Type
    Experimental
    Arm Description
    An oral glucose challenge (75 g)
    Arm Title
    GIP Bolus
    Arm Type
    Active Comparator
    Arm Description
    Hyperglycemic clamp (capillary venous glucose concentration ~ 8.5 mmol/l) with two repeated intravenous bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
    Arm Title
    GIP Infusion
    Arm Type
    Active Comparator
    Arm Description
    Hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
    Intervention Type
    Drug
    Intervention Name(s)
    GIP Bolus
    Intervention Description
    bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
    Intervention Type
    Drug
    Intervention Name(s)
    GIP Clamp
    Intervention Description
    hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
    Intervention Type
    Procedure
    Intervention Name(s)
    Oral glucose tolerance test (OGTT)
    Intervention Description
    an oral glucose challenge (75 g)
    Intervention Type
    Procedure
    Intervention Name(s)
    hyperglycemic clamp
    Intervention Description
    a hyperglycemic clamp (capillary venous glucose concentration ~ 8.5 mmol/l)
    Primary Outcome Measure Information:
    Title
    Insulin secretory response after GIP bolus or infusion.
    Time Frame
    210 minutes

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Exclusion of pregnancy Exclusion of impaired glucose tolerance or type 2 diabetes in metabolical healthy subjects current diagnosis of type 2 diabetes according to the guidelines of the German Diabetes Association (DDG) ( Kerner et al . 2001) in subjects of diabetes group fasting glucose ≤ 150 mg/dl Body-mass-index ≥ 20 kg/m² Written consent Exclusion Criteria: Type 1 diabetes Impaired glucose tolerance or Type 2 diabetes in metabolical healthy subjects Ketone bodies urine diagnostics at least ++ Acidosis Fasting blood glucose > 150 mg/dl Body-mass-index < 20 kg/m² No written consent Pregnancy or unsafe contraception in women before menopause Active malignancy Angina as current, unsolved clinical problem Inadequately treated or untreated arterial hypertension ( > 160 mmHg systolic and / or > 95 mmHg diastolic ) Infection / fever > 37.5 ° C Treatment with glucocorticoids Insulin therapy within the last three months Anemia with a hemoglobin level < 12 g/dl Liver function limitations Renal impairment ( serum creatinine > 1.5 mg/dl ) Alcohol or drug abuse Participation in clinical trials in the last 3 months Inability or unwillingness to comply with the requirements of the Protocol Known hypersensitivity to GIP
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Michael A. Nauck, Prof.
    Organizational Affiliation
    Diabeteszentrum Bad Lauterberg
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP

    We'll reach out to this number within 24 hrs